- 2017
- Chen B, Wei W, Ma L, Yang B, Gill RM, Chua M-S, Butte AJ, So S.Computational Discovery of Niclosamide Ethanolamine, A Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells in Vitro and in Mice by Inhibiting CDC37 Signaling, Gastroenterology (2017), doi: 10.1053/j.gastro.2017.02.039.
- 2015
- Lu WJ, Chua MS, Wei W, So SK. NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation. Oncotarget. 2015 Oct 6;6(30):29847-59.
- Lu WJ, Chua MS, So SK. Suppression of ATAD2 inhibits hepatocellular carcinoma progression through activation of p53- and p38-mediated apoptotic signaling. Oncotarget. 2015 Dec 8;6(39):41722-35.
- Ma L, Wang X, Jia T, Wei W, Chua MS, So S. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells. Oncotarget. 2015 Sep 22;6(28):25390-401.
- Wang Z, Wei W, Sun CK, Chua MS, So S. Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth. Liver Int. 2015 Apr;35(4):1403-15.
- Yung MK, Lo KW, Yip CW, Chung GT, Tong CY, Cheung PF, et al. Copy number gain of granulin-epithelin precursor (GEP) at chromosome 17q21 associates with overexpression in human liver cancer BMC CANCER .2015; 15:264
- 2014
- Ma L, Chua MS, Andrisani O, So S. Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives. World J Gastroenterol. 2014 Jan 14;20(2):333-45.
- Yang X, Liu H, Sun CK, Natarajan A, Hu X, Wang X,et al. Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹Zr-labeled anti-glypican- 3 monoclonal antibody. Biomaterials. 2014 Aug;35(25):6964-71.
- Sun CK, Chua MS, Wei W and So SK. Glypican-3-Mediates Autophagy and Promotes Self-Renewal and Tumor Initiation of Hepatocellular Carcinoma Cells. Journal of Stem Cell Research & Therapy.
- Wei W, Wu S, Wang X, Sun CK, Yang X, Yan X, Chua MS, So S. Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts. Oncotarget. 2014 Jul 30;5(14):5819-31.
- Lu WJ, Chua MS, So SK. Suppressing N-Myc downstream regulated gene 1 reactivates senescence signaling and inhibits tumor growth in hepatocellular. Carcinogeneis.2014; 35(4):915-22.
- 2013
- Zhao P, Yang X, Qi S, Liu H, Jiang H, Hoppmann S, et al. Molecular imaging of hepatocellular carcinoma xenografts with epidermal growth factor receptor targeted affibody probes. Biomed Res Int. 2013;2013:759057.
- 2012
- Bu L, Xie J, Chen K, Huang J, Aguilar ZP, Wang A, et al. Assessment and comparison of magnetic nanoparticles as MRI contrast agents in a rodent model of human hepatocellular carcinoma. Contrast Media Mol Imaging. 2012;7(4):363-72.
- Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109(17):6662-7.
- 2011
- Wei W, Chua MS, Grepper S, So SK. Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. Mol Cancer. 2011;10:16.
- Sun CK, Chua MS, He J, So SK. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-beta2. Neoplasia. 2011;13(8):735-47.
- 2010
- Wei W, Chua MS, Grepper S, So S. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int J Cancer. 2010;126(10):2426-36.
- 2009
- Wei W, Chua MS, Grepper S, So SK. Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer. 2009;8:76.
- 2008
- Sun H, Chua MS, Yang D, Tsalenko A, Peter BJ, So S. Antibody Arrays Identify Potential Diagnostic Markers of Hepatocellular Carcinoma. Biomark Insights. 2008 Jan 21;3:1-18. PubMed PMID: 19578489; PubMed Central PMCID: PMC2688354.
- Yan X, Chua MS, Sun H, So S. N-Myc down-regulated gene 1 mediates proliferation, invasion, and apoptosis of hepatocellular carcinoma cells. Cancer Lett. 2008 Apr 8;262(1):133-42. doi: 10.1016/j.canlet.2007.12.010. PubMed PMID: 18207320.
- Yan X, Chua MS, He J, So SK. Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo. Mol Cancer. 2008 Feb 12;7:19. doi: 10.1186/1476-4598-7-19. PubMed PMID: 18269767; PubMed Central PMCID: PMC2276234.
- 2007
- Chua MS, Sun H, Cheung ST, Mason V, Higgins J, Ross DT, Fan ST, So S. Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. Mod Pathol. 2007 Jan;20(1):76-83. PubMed PMID: 17170744
- 2006
- Fong CW, Chua MS, McKie AB, Ling SH, Mason V, Li R, Yusoff P, Lo TL, Leung HY, So SK, Guy GR. Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res. 2006 Feb 15;66(4):2048-58. PubMed PMID: 16489004.
- Chua MS, Bernstein LR, Li R, So SK. Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Res. 2006 May-Jun;26(3A):1739-43. PubMed PMID: 16827101.
- 2005
- Patil MA, Chua MS, Pan KH, Lin R, Lih CJ, Cheung ST, Ho C, Li R, Fan ST, Cohen SN, Chen X, So S. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene. 2005 May 26;24(23):3737-47. PubMed PMID: 15735714.
-
- 2017
- National Academies of Sciences, Engineering, and Medicine. 2017. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report. Washington, DC: The National Academies Press. doi: 10.17226/24731
- 2016
- National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the public health problem of hepatitis B and C in the United States: Phase one report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
- Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081-8.
- Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al.Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2016.
- Wang J, Feng Q, Tam A, Sun T, Zhou P, So S. Evaluation of the first open-access hepatitis B and safe injection online training course for health professionals in China. BMC Med Educ. 2016;16:81.
- 2015
- Chao SD, Wang BM, Chang ET, Ma L, So SK. Medical training fails to prepare providers to care for patients with chronic hepatitis B infection. World J Gastroenterol. 2015;21(22):6914-23.
- Toy M, Hutton DW, So SK. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. PLoS One. 2015;10(11):e0139876.
- GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71.
- 2014
- Toy M, Demirci U, So S. Preventing hepatocellular carcinoma: the crucial role of chronic hepatitis B monitoring and antiviral treatment. Hepatic Oncology. 2014; 1 (3): 255-257.
- 2011
- Bailey MB, Shiau R, Zola J, Fernyak SE, Fang T, So SK, et al. San Francisco hep B free: a grassroots community coalition to prevent hepatitis B and liver cancer. J Community Health. 2011;36(4):538-51
- Hutton DW, Brandeau ML, So SK. Doing Good with Good OR: Supporting Cost-effective Hepatitis B Interventions. Interfaces (Providence). 2011;41(3):289-300.
- 2010
- IOM (Institute of Medicine). 2010. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academies Press.
- Hutton DW, So SK, Brandeau ML. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology. 2010;51(2):405-14.
- Chang ET, Yang J, Alfaro-Velcamp T, So SK, Glaser SL, Gomez SL. Disparities in liver cancer incidence by nativity, acculturation, and socioeconomic status in California Hispanics and Asians. Cancer Epidemiol Biomarkers Prev. 2010;19(12):3106-18.
- Chao J, Chang ET, So SK. Hepatitis B and liver cancer knowledge and practices among healthcare and public health professionals in China: a cross-sectional study. BMC Public Health. 2010;10:98.
-
